Erratum: Stereoselective binding of mexiletine and ketoprofen enantiomers with human serum albumin domains (Acta Pharmacologica Sinica (2012) 33:5 (710-716) DOI: 10.1038/aps.2012.8);Stereoselective binding of mexiletine and ketoprofen enantiomers with human serum albumin domains

Acta Pharmacologica Sinica

Volumn 33, Issue 5, 2012, Pages 710-716

  Shi, Da ^a   Jin, Yin Xiu ^b   Tang, Yi Hong ^c   Hu, Hai Hong ^a   Xu, Si Yun ^a   Yu, Lu Shan ^a   Jiang, Hui Di ^a   Zeng, Su ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b TAIZHOU UNIVERSITY   (China)

^c SHANGHAI INSTITUTE OF TECHNOLOGY   (China)

Author keywords

Human serum albumin; Ketoprofen; Mexiletine; Pichia pastoris GS115 cells; Protein binding; Stereoselectivity; Ultrafiltration technique

Indexed keywords

DIAZEPAM; DIGITOXIN; KETOPROFEN; MEXILETINE; PHENYLBUTAZONE; SERUM ALBUMIN;

ARTICLE; BINDING AFFINITY; CHIRALITY; DRUG PROTEIN BINDING; ENANTIOMER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PICHIA PASTORIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; ULTRAFILTRATION; WESTERN BLOTTING;

EID: 84860714839     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.37     Document Type: Erratum

References (36)

1. He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature 1992; 358: 209-15.
2. Caner H, Groner E, Levy L, Agranat I. Trends in the development of chiral drugs. Drug Discov Today 2004; 9: 105-10. (Pubitemid 38198306)
3. Igwemezie L, Kerr C, McErlane K. The pharmacokinetics of the enantiomers of mexiletine in humans. Xenobiotica 1989; 19: 677-82. (Pubitemid 19147786)
4. Hong Y, Tang Y, Zeng S. Enantioselective plasma protein binding of propafenone: mechanism, drug interaction, and species difference. Chirality 2009; 21: 692-8.
5. Sun DL, Huang SD, Wu PS, Li J, Ye YJ, Jiang HD. Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma. Chirality 2010; 22: 618-23.
6. Chuang VTG, Otagiri M. Stereoselective binding of human serum albumin. Chirality 2006; 18: 159-66. (Pubitemid 43334159)
7. Reed RG, Feldhoff RC, Clute O, Peters Jr T. Fragments of bovine serum albumin produced by limited proteolysis. Conformation and ligand binding. Biochemistry 1975; 14: 4578-83.
8. Bos OJM, Fischer MJE, Wilting J, Janssen LHM. Drug-binding and other physicochemical properties of a large tryptic and a large peptic fragment of human serum albumin. BBA-Protein Struct M 1988; 953: 37-47. (Pubitemid 18051926)
9. Bos OJM, Remijn JPM, Fischer MJE, Wilting J, Janssen LHM. Location and characterization of the warfarin binding site of human serum albumin: A comparative study of two large fragments. Biochem Pharmacol 1988; 37: 3905-9.
10. Bos O, Labro J, Fischer M, Wilting J, Janssen L. The molecular mechanism of the neutral-to-base transition of human serum albumin. Acid/base titration and proton nuclear magnetic resonance studies on a large peptic and a large tryptic fragment of albumin. J Biol Chem 1989; 264: 953.
11. Dockal M, Carter DC, Ruker F. The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem 1999; 274 : 29303-10.
12. Dockal M, Chang M, Carter DC, Rüker F. Five recombinant fragments of human serum albumin-tools for the characterization of the warfarin binding site. Protein Sci 2000; 9: 1455-65. (Pubitemid 30659184)
13. Il'ichev YV, Perry JL, Rüker F, Dockal M, Simon JD. Interaction of ochratoxin A with human serum albumin. Binding sites localized by competitive interactions with the native protein and its recombinant fragments. Chem-Biol Interact 2002; 141: 275-93. (Pubitemid 35217765)
14. Matsushita S, Isima Y, Chuang V TG, Watanabe H, Tanase S, Maruyama T, et al. Functional analysis of recombinant human serum albumin domains for pharmaceutical applications. Pharm Res 2004; 21: 1924-32. (Pubitemid 39390105)
15. Liu R, Meng Q, Xi J, Yang J, Ha CE, Bhagavan NV, et al. Comparative binding character of two general anaesthetics for sites on human serum albumin. Biochem J 2004; 380: 147.
16. Twine S, Gore M, Morton P, Fish B, Lee A, East J. Mechanism of binding of warfarin enantiomers to recombinant domains of human albumin. Arch Biochem Biophys 2003; 414: 83-90. (Pubitemid 36555448)
17. Rendic S, Albic-Kolbah T, Kajfez F, Sunjic V. Stereoselective binding of and (f)-alpha-(benzoylphenylpropionic) acid (ketoprofen) to human serum albumin. Farmaco, Edizione Scientifica 1980; 35: 51-9. (Pubitemid 10151441)
18. Verbeeck R, Blackburn J, Loewen G. Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1983; 8: 297.
19. Dubois N, Lapicque F, Abiteboul M, Netter P. Stereoselective protein binding of ketoprofen: effect of albumin concentration and of the biological system. Chirality 1993; 5: 126-34. (Pubitemid 23183370)
20. Sakai T, Maruyama T, Imamura H, Shimada H, Otagiri M. Mechanism of stereoselective serum binding of ketoprofen after hemodialysis. J Pharmacol Exp Ther 1996; 278: 786.
21. Zhivkova ZD, Russeva VN. Stereoselective binding of ketoprofen enantiomers to human serum albumin studied by high-performance liquid affinity chromatography. J Chromatogr B 1998; 714: 277-83. (Pubitemid 28386849)
22. Hayball PJ, Nation RL, Bochner F, Newton JL, Massy-Westropp RA, Hamon DPG. Plasma protein binding of ketoprofen enantiomers in man: method development and its application. Chirality 1991; 3: 460-6.
23. Lapicque F, Muller N, Payan E, Dubois N, Netter P. Protein binding and stereoselectivity of nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1993; 25: 115.
24. Zou H, Wang H, Zhang Y. Stereoselective binding of warfarin and ketoprofen to human serum albumin determined by microdialysis combined with HPLC. J Liq chromatogr R T 1998; 21: 2663-74. (Pubitemid 28458106)
25. Kwok D, Kerr C, McErlane K. Pharmacokinetics of mexiletine enantiomers in healthy human subjects. A study of the in vivo serum protein binding, salivary excretion and red blood cell distribution of the enantiomers. Xenobiotica 1995; 25: 1127-42.
26. Grech-Belanger O, Turgeon J, Gilbert M. Stereoselective disposition of mexiletine in man. Brit J Clin Pharmaco 1986; 21: 481.
27. McErlane K, Igwemezie L, Kerr C. Stereoselective serum protein binding of mexiletine enantiomers in man. Res Commun Chem Pathol Pharmacol 1987; 56: 141.
28. Jin YX, Tang YH, Zeng S. Analysis of flurbiprofen, ketoprofen and etodolac enantiomers by pre-column derivatization RP-HPLC and application to drug-protein binding in human plasma. J Pharmaceut Biomed 2008; 46: 953-8.
29. Jin YX, Zeng S. Determination of mexiletine enantiomers in human serum albumin after derivatization with GITC by RP-HPLC. Chinese Pharmaceutical Journal 2007. Chinese.
30. Guo CC, Tang YH, Hu HH, Yu LS, Jiang HD, Zeng S. Analysis of chiral non-steroidal anti-inflammatory drugs flurbiprofen, ketoprofen and etodolac binding with HSA. J Pharmaceut Anal; 1: 184-90.
31. Jin YX. Enantioselective binding of chiral drugs, mexiletine and ketoprofen, to plasma proteins. Thesis for master degree. Zhejiang University. 2006. p 24-31. Chinese.
32. Hutt A, Caldwell J. The importance of stereochemistry in the clinical pharmacokinetics of the 2-arylpropionic acid non-steroidal antiinflammatory drugs. Clin Pharmacokinet 1984; 9: 371-3. (Pubitemid 14091203)
33. Rudy AC, Liu Y, Brater C, Hall SD. Stereoselective pharmacokinetics and inversion of (R)-ketoprofen in healthy volunteers. J Clin Pharmacol 1998; 38: 3S.
34. Jamali F, Brocks D. Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin Pharmacokinet 1990; 19: 197.
35. Grubb N, Rudy D, Brater D, Hall S. Stereoselective pharmacokinetics of ketoprofen and ketoprofen glucuronide in end-stage renal disease: evidence for a 'futile cycle' of elimination. Br J Clin Pharmacol 1999; 48: 494-500. (Pubitemid 29454228)
36. Bannwarth B, Lagrange F, Péhourcq F, Llanas B, Demarquez J. (S)-ketoprofen accumulation in premature neonates with renal failure who were exposed to the racemate during pregnancy. Br J Clin Pharmacol 1999; 47: 459-60. (Pubitemid 29161282)